The FDA has placed a partial clinical hold on the phase III AIM2CERV trial evaluating the use of axalimogene filolisbac in patients with high-risk locally advanced cervical cancer.
Original Article: FDA Places Partial Hold on Cervical Cancer Trial of AIM2CERV